Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Advanced Bile Duct or Gallbladder Cancer
NCT00085410Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Aug 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in cholangiocarcinoma (CCA) and Adenocarcinoma Of The Gallbladder, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 1 year. Started Jan 2004; status: terminated.
02
Drugs
bortezomib
03
Conditions
cholangiocarcinoma (CCA)Adenocarcinoma Of The Gallbladder
Beyond the preview
Go deeper on NCT00085410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085410.